Patients under 21 with breast or colorectal cancer more likely to have aggressive disease
the ONA take:
According to two studies presented at the 2014 Clinical Congress of the American College of Surgeons in San Francisco, California, when breast and colorectal cancers occur in children, the diseases are aggressive.
Researchers at Seattle Children's Hospital in Seattle, Washington sought to investigate how breast cancer progresses when diagnosed in patients under age 21. Researchers identified 574 patients aged 21 or younger with breast cancer from the National Cancer Data Base of the American College of Surgeons and American Cancer Society. Results showed that younger patients were more likely to be African American, male, and uninsured.
Furthermore, these patients had worse outcomes that adult patients. Researchers also found a large delay between surgical treatment and radiation therapy. The delay is something the researchers hope to investigate further.
The other study was conducted by researchers at the Maine Medical Center in Portland, Maine who wanted to assess the outcomes of younger patients diagnosed with colorectal cancer. They identified 920 patients age 21 or younger. They found that younger patients were more likely diagnosed with advanced disease and found to have more aggressive tumors. Pediatric patients also had lower 5-year survival rates compared young adults.
When breast and colorectal cancers occur in children, the diseases are aggressive.
Breast and colorectal cancers rarely occur in children, but when they do, these conditions are more precarious, according to a pair of National Cancer Data Base (NCDB) studies presented this week at the 2014 Clinical Congress of the American College of Surgeons. Both breast cancer and colon cancer are known as adult conditions.
According to the American Cancer Society, 95 percent of new breast cancer cases occur in women age 40 and older. Colorectal cancer is also largely an adult cancer, with 90 percent of cases occurring in people who are age 50 and older.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|